Stockscreener 앱 받기
33.05
4.65%
1.47
시간 외 거래:
33.35
0.30
+0.91%
Olema Pharmaceuticals Inc 주식(OLMA)의 최신 뉴스
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $48.00 - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Raised to $60.00 - MarketBeat
OLMA Stock: Citigroup Raises Price Target to $60, Maintains Buy Rating | OLMA Stock News - GuruFocus
Olema Pharmaceuticals (OLMA): HC Wainwright & Co. Raises Price T - GuruFocus
Olema Oncology (OLMA) Price Target Raised by Citi Amid Positive Trial Data - GuruFocus
Oppenheimer Raises Price Target for Olema Pharmaceuticals (OLMA) to $48 | OLMA Stock News - GuruFocus
OLMA: Goldman Sachs Raises Price Target to $38 on Maintained Buy Rating | OLMA Stock News - GuruFocus
The Goldman Sachs Group Issues Positive Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 6% Following Analyst Upgrade - MarketBeat
Olema (OLMA) Hits 4-Year High as Jefferies Hikes PT - Finviz
HC Wainwright Raises Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $45.00 - MarketBeat
HighVista Strategies LLC Acquires 66,245 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Jefferies raises Olema Pharmaceuticals stock price target to $43 on SERD validation - Investing.com UK
Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 1-Year HighHere's Why - MarketBeat
Olema Oncology (OLMA) Shares Surge Over 11% - GuruFocus
Olema Pharmaceuticals stock hits 52-week high at $29.57 By Investing.com - Investing.com Canada
Roche's SERD Trial Boosts Olema Pharmaceuticals (OLMA) Stock - GuruFocus
Olema Pharmaceuticals stock hits 52-week high at $29.57 - Investing.com
Diadema Partners LP Increases Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Sets New Standards In Oncology - Kalkine Media
Olema Pharmaceuticals joins SABCS25 to advance breast cancer therapies - Traders Union
Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 7.7%Here's Why - MarketBeat
Olema Pharmaceuticals (NASDAQ:OLMA) Moves Forward with Clinical Trials - Kalkine Media
XTX Topco Ltd Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals, Inc. $OLMA Shares Bought by Schroder Investment Management Group - MarketBeat
Affinity Asset Advisors LLC Lowers Holdings in Olema Pharmaceuticals, Inc. $OLMA - MarketBeat
Olema Pharmaceuticals (OLMA) price target increased by 53.92% to 37.23 - MSN
Olema Pharmaceuticals Inc Stock Analysis and ForecastVolume Profile Analysis & Turn Data into Profits With Our Strategies - earlytimes.in
Why Olema Pharmaceuticals Inc. stock is rated strong buyChart Signals & Capital Protection Trade Alerts - Newser
Why retail investors favor Olema Pharmaceuticals Inc. stockMarket Sentiment Review & Long-Term Growth Plans - Newser
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Olema Pharmaceuticals seeks senior medical director to advance oncology care - Traders Union
Olema Pharmaceuticals (OLMA) Stock Analysis Report | Financials & Insights - Benzinga
H.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials Advance - MSN
Olema Pharmaceuticals (OLMA): Assessing Valuation Following $190 Million Equity Offering and Underwriter Changes - Sahm
Olema Pharmaceuticals (NASDAQ:OLMA) Reaches New 1-Year HighHere's What Happened - MarketBeat
Will Olema Pharmaceuticals Inc. stock pay special dividends2025 Price Targets & Weekly Watchlist for Hot Stocks - BỘ NỘI VỤ
Olema Pharmaceuticals stock hits 52-week high at 27.25 USD By Investing.com - Investing.com Canada
Olema Pharmaceuticals stock hits 52-week high at 27.25 USD - Investing.com
15,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Bought by Titleist Asset Management LLC - MarketBeat
Olema Pharmaceuticals : Statement of Changes in Beneficial Ownership (Form 4) - marketscreener.com
Dir Rappaport Acquires 35,868 Of Olema Pharmaceuticals Inc [OLMA] - TradingView
[Form 4] Olema Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Olema Pharmaceuticals Reports Increased Losses Amid R&D Expansion - MSN
Olema Pharmaceuticals (OLMA): Evaluating the Current Valuation After a Strong Run-Up in Recent Months - Yahoo Finance
Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) - MSN
LifeSci Capital Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA) - The Globe and Mail
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
The Goldman Sachs Group Boosts Olema Pharmaceuticals (NASDAQ:OLMA) Price Target to $26.00 - MarketBeat
Olema Oncology to Participate in Upcoming Investor Conferences - Sahm
Research Analysts Set Expectations for OLMA Q1 Earnings - MarketBeat
Goldman Sachs Maintains Olema Pharmaceuticals (OLMA) Buy Recommendation - MSN
Olema Pharmaceuticals Inc. (OLMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference - The Manila Times
Small Cap Stocks To Keep An Eye OnNovember 18th - MarketBeat
Goldman Sachs Raises Price Target for Olema Pharmaceuticals (OLM - GuruFocus
Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 26%What's Next? - MarketBeat
Commit To Purchase Olema Pharmaceuticals At $16, Earn 40.4% Annualized Using Options - Nasdaq
1.08%
0.91%
자본화:
|
볼륨(24시간):